WASHINGTON, DC – The US Food and Drug Administration has approved two clinical trials to assess the efficacy of cannabidiol (CBD), a nonpsychoactive plant cannabinoid, in the treatment of intractable pediatric epilepsy. The two approved trials will take place at New York Medical School and at the University of California at San Francisco, according to an online report in the […]
Read FDA Approves Clinical Trials Assessing CBD for Pediatric Epilepsy in its entirety on The Daily Chronic.
Want to stay up to date on marijuana reform & cannabis news worldwide? Visit The Daily Chronic - The Voice of the Reform Generation, the most comprehensive coverage of the cannabis community!
SOURCE: FDA Approves Clinical Trials Assessing CBD for Pediatric Epilepsy by NORML
. . . . . READ MORELONDON, UNITED KINGDOM – Hundreds of users of medical marijuana protested outside Parliament last week to demand changes to Britain’s strict cannabis laws, a move many experts believe could yield billions of pounds in tax revenue and save the government billions in policing costs. Under current law, it is illegal for British citizens to consume or […]
Read Marijuana Reform Could Earn UK Billions a Year, Studies Say in its entirety on The Daily Chronic.
Want to stay up to date on marijuana reform & cannabis news worldwide? Visit The Daily Chronic - The Voice of the Reform Generation, the most comprehensive coverage of the cannabis community!
SOURCE: Marijuana Reform Could Earn UK Billions a Year, Studies Say by Bernd Debusmann, Jr.
. . . . . READ MORELONDON, UK — GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, is pleased to note the announcement from its partner Almirall S.A. that Sativex® is now available in Italy as a prescription medicine for use in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications.
The launch follows receipt of full marketing authorization for Sativex® by the Italian health authorities in May. The medicine is reimbursed by the Italian authorities as a Class H (hospital dispensed) medicine. The reimbursed price of the medicine granted by the authorities in Italy is consistent with the reimbursed Sativex® price in Spain.
“As one of the largest markets in Europe, the launch of Sativex® in Italy is a key milestone in the commercialization of this important new medicine. Italy represents yet another addition to the growing number of countries in Europe in which Sativex® is now available to treat MS spasticity, a particularly debilitating symptom of MS that is not adequately treated with currently available medications,” stated Justin Gover, Chief Executive Officer of GW. “With a total of 21 countries that have now approved Sativex® for use in the treatment of MS spas. . . . . READ MORE